1. Adjusted treatment outcomes including (A) OS, (B) PFS, (C) TTD, and (D)
DOR* in the overall population (≥1% PD-L1 expression; N=484).
2. Adjusted treatment outcomes, including (A) OS, (B) PFS, (C) TTD, and (D)
DOR* in the low-to-moderate PD-L1 subgroup (1%-49% PD-L1 expression; N=183).
3. Adjusted treatment outcomes, including (A) OS, (B) PFS, (C) TTD, and (D)
DOR* in the high PD-L1 subgroup (≥50% PD-L1 expression; N=301).
patterns and outcomes in PD-L1–positive non-small cell lung cancer
report real-world treatment patterns and outcomes in patients with PD-L1+
retrospective, observational study using the ConcertAI Oncology Dataset,
included patients with PD-L1+ (≥1% expression) metastatic NSCLC who began
first-line (1L) treatment between 2016-2019. Treatment outcomes were assessed
by treatment class (immune checkpoint inhibitor [ICI] monotherapy, ICI
combinations, or chemotherapy).
In total, 128 (25.5%), 237 (47.3%) and 136
patients (27.1%) received 1L chemotherapy, 1L ICI monotherapy, and 1L ICI
combinations, respectively. ICI combinations and monotherapy had improved
clinical outcomes vs chemotherapy. Adjusted analyses showed no significant
difference in outcome between ICI monotherapy and ICI combinations.
ICI-based treatments are being increasingly
adopted into clinical practice and were associated with better outcomes vs